Clinical trials recruiting for HER2 + Breast Cancer

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer
  NCT07081555 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 3 locations
• A Phase 1/1b Study of IAM1363 in HER2 Cancers
  NCT06253871 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
  NCT05534438 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
  NCT07294508 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Breast Cancer Evolution During Neoadjuvant Systemic Therapy
  NCT06681064 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
  NCT07211178 · Phase: Not specified · Ages: 18 Years to 99 Years · Sex: All (male and female) · 16 locations
• HER2-positive Breast Cancer Registry
  NCT06603597 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
  NCT07393425 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
  NCT07695259 · Phase: Phase 4 · Ages: 60 Years and older · Sex: Female · 1 location
• Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
  NCT07739511 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
  NCT07222215 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study
  NCT07030569 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
  NCT07065435 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
  NCT07600164 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations

Related conditions

Trials recruiting for HER2 + Breast Cancer often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for HER2 + Breast Cancer trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.